Transfusion medicine: Looking to the future

Lancet

Volumn 361, Issue 9352, 2003, Pages 161-169

  Goodnough, Lawrence T ^a   Shander, Aryeh ^b   Brecher, Mark E ^c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ENGLEWOOD HOSPITAL AND MEDICAL CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN III; DIASPIRIN CROSSLINKED HEMOGLOBIN; ERYTHROPOIETIN; FLUOROCARBON; GLUTARALDEHYDE; HEMOGLOBIN; MACROGOL; OXYGEN; PERFLUOROOCTYL BROMIDE; POLYMER; POLYMERIZED HEMOGLOBIN; RAFFINOSE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; RECOMBINANT HEMOGLOBIN;

ANEMIA; BACTERIUM CONTAMINATION; BLOOD DONOR; BLOOD SUBSTITUTION; CHAGAS DISEASE; CLINICAL TRIAL; DEVELOPING COUNTRY; ERROR; ERYTHROPOIESIS; EVOLUTION; HEALTH CARE AVAILABILITY; HEALTH CENTER; HEALTH SERVICE; HEMOSTASIS; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MEDICAL SPECIALIST; MORTALITY; PATIENT CARE; POLYMERIZATION; PRIORITY JOURNAL; REVIEW; SAFETY; SCREENING; SEROPREVALENCE; TECHNOLOGY; THROMBOCYTE; TRYPANOSOMA CRUZI; VASCULARIZATION; VIRUS TRANSMISSION;

EID: 0037431753     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12195-2     Document Type: Review

References (101)

1. Schmidt P.J. Blood and disaster: supply and demand. N Engl J Med. 346:2002;617-620.
2. Klein H.G. Earthquake in America. Transfusion. 41:2001;1179-1180.
3. Chapman J. Monitoring the capacity of the blood supply to meet demand. Presentation at the HHS Advisory Committee on Blood Safety and Availability. What lessons can be learned from the events of Sept 11, 2001, that would strengthen the safety and availability of the US blood supply? Transcript of 16th meeting. Vol I, Jan 31, 2002. http://www.hhs.gov/bloodsafety/transcripts/20020131.html (accessed Jan 5, 2002).
4. Nightingale S. The federal government role in assuring blood safety and availability during a disaster. Presentation at the HHS Advisory Committee on Blood Safety and Availability. What lessons can be learned from the events of Sept 11, 2001, that would strengthen the safety and availability of the US blood supply? Transcript of 16th meeting. Vol I, Jan 31, 2002. http://www.hhs.gov/bloodsafety/transcripts/20020131.html (accessed Jan 5, 2002).
5. Goodnough L.T., Brecher M.E., Kanter M.H., Aubuchon J.P. Transfusion medicine: part I. N Engl J Med. 340:1999;438-447.
6. Ouellette G. The experience and actions of the Washington, DC, blood community on and after September 11. Presentation at the HHS Advisory Committee on Blood Safety and Availability. What lessons can be learned from the events of Sept 11, 2001, that would strengthen the safety and availability of the US blood supply? Transcript of 16th meeting. Vol I, Jan 31, 2002. http://www.hhs.gov/bloodsafety/transcripts/20020131.html (accessed Jan 5, 2002).
7. Gilcher R. Lessons from previous disasters. Presentation at the HHS Advisory Committee on Blood Safety and Availability. What lessons can be learned from the events of Sept 11, 2001, that would strengthen the safety and availability of the US blood supply? Transcript of 16th meeting. Vol I. Jan 31, 2002. http://www.hhs.gov/bloodsafety/transcripts/20020131.html (accessed Jan 5, 2002).
8. Valeri C.R., Ragno G., Pivacek L.E., et al. A multicenter study of in vitro and in vivo values in human RBCs frozen with 40-percent (wt/vol) glycerol and stored after deglycerolization for 15 days at 4 degrees C in AS-3: assessment of RBC processing in the ACP 215. Transfusion. 41:2001;933.
9. Snyder E Blood community perspective on assuring blood safety and availability during a disaster. Presentation at the HHS Advisory Committee on Blood Safety and Availability. What lessons can be learned from the events of Sept 11, 2001, that would strengthen the safety and availability of the US blood supply? Transcript of 16th meeting. Vol I. Jan 31, 2002. http://www.hhs.gov/bloodsafety/transcripts/20020131.html (accessed Jan 5, 2002).
10. Kleinman S.H., Glynn S.A., Busch M.P., Wright O.J., McMullen Q., Schreiber G.B. Declining incidence rates and risks of transfusion-transmitted viral infections in US blood donors. Vox Sang. 83:2002;106.
11. Aubuchon J.P., Birkmeyer J.D., Busch M.P. Safety of the blood supply in the United States: opportunities and controversies. Ann Intern Med. 127:1997;904-909.
12. CBS News. HIV-tainted blood infects two in Florida. http://www.cbsnews.com/stories/2002/07/19/health/main515694.shtml (accessed Dec 6, 2002).
13. da Silva Cardoso M., Koerner K., Kubanek B. The first case of HCV seroconversion after 3 years of HCV NAT screening in Baden-Wurttemberg. Transfusion. 40:2000;1422-1423.
14. Yomtovian R., Lazarus H.M., Goodnough L.T., et al. A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets. Transfusion. 33:1993;902-909.
15. Dyskstra A., Jacobs J., Yomtovian R. Prospective microbiological surveillance (PMS) of random donor (RDP) and single donor apheresis platelets (SDP). Transfusion. 38:(suppl):1998;S104.
16. Leiby D.A., Kerr K.L., Campos J.M., et al. A retrospective analysis of microbial contaminants in outdated random-donor platelets from multiple sites. Transfusion. 37:1997;259-263.
17. Goldman M., Blajchman M.A. Blood product-associated bacterial sepsis. Transfus Med Rev. 5:1991;73-83.
18. Association Bulletin No 96-6. Bacterial contamination of blood components. AABB Faxnet, No 294, August, 1996. American Association of Blood Banks.
19. Jacobs M.R., Palavecino E., Yomtovian R. Don't bug me: the problem of bacterial contamination of blood components-challenges and solutions. Transfusion. 41:2001;1331-1334.
20. Ness P.M., Braine H.G., King K., et al. Single donor platelets reduce the risk of septic transfusion reactions. Transfusion. 41:2001;857-861.
21. Ollgaard M., Albjerg I., Georgen J. Monitoring of bacterial growth in platelet concentrates - one year's experience with the BactAlertTM System. Vox Sang. 74:(suppl):1998;1126.
22. Laan E., Tros C. Improved safety and extended shelf-life of leuco-depleted platelet concentrates by automated bacterial screening. Transfusion. 39:(suppl):1999;5S.
23. Vuetic D., Taseki J., Balint B., Mirovic V. The use of BacTAlert system for bacterial screening in platelet concentrates. Vox Sang. 78:(suppl):2000;P371.
24. McDonald C.P., Roy A., Lowe P., et al. The first experience in the United Kingdom of the bacteriological screening of platelets to increase shelf life to 7 days. Vox Sang. 78:(suppl):2000;P375.
25. Brecher M.E., Means N., Jere C.S., et al. Evaluation of the BacT/ALERT 3D microbial detection system for platelet bacterial contamination: an analysis of 15 contaminating organisms. Transfusion. 41:2001;477-482.
26. AuBuchon J.P., Cooper L.K., Leach M.F., et al. Bacterial culture of platelet units and extension of storage to 7 days. Transfusion. 41:(suppl):2001;S1.
27. Brecher M.E., Holland P.V., Pineda A., et al. Bacterial growth in inoculated platelets: Implications for bacterial detection and the extension of platelet storage. Transfusion. 40:2000;1308-1312.
28. Lin L., Cook D.N., Wiesehahn G.P., et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion. 37:1997;423-435.
29. Knutson F., Alfonso R., Dupuis K., et al. Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function. Vox Sang. 78:2000;209-216.
30. Corash L., Behrman B., Rheinschmidt M., et al. Post-transfusion viability and tolerability of photochemically treated platelet concentrates. Blood. 90:1997;267a.
31. McCullough J., Vesole D., Benjamin R.J., et al. Pathogen-inactivated platelets using Helinx technology are hemostatically effective in the thrombocytopenia patient. Blood. 98:2001;45a.
32. Nahlen B.L., Lobel H.O., Cannon S.E., Campbell C.C. Reassessment of blood donor selection criteria for United States travelers to malarious areas. Transfusion. 31:1991;786-788.
33. Guerrero I.C., Weneger B.G., Schultz M.G. Transfusion malaria in the United States, 1972-1981. Ann Intern Med. 99:1983;221.
34. Mungai M., Tegtmeier G., Chamberland M., Parise M. Transfusion-transmitted malaria in the United States from 1963 through 1999. N Engl J Med. 344:2001;1973-1978.
35. Schmunis G.A. Trypanosomo cruzi, the etiologic agent of Chagas' disease: status in the blood supply in endemic and non-endemic countries. Transfusion. 31:1991;547-557.
36. Schmunis G.A., Zueker F., Cruz J.R., Cuchi P. Safety of blood supply for infectious disease in Latin American countries. Am J Trop Med Hyg. 65:2001;924-930.
37. Shulman I.A., Appelman S., Saxena S., Hiti A.L., Kirchhoff L.V. Specific antibodies to Trypansoma cruzi among blood donors in Los Angeles, California. Transfusion. 37:1997;727-731.
38. Cimo P.L., Luper W.E., Scouroso M.A. Transfusion-associated Chagas' disease in Texas: report of a case. Tex Med J. 89:1993;48-50.
39. Chagas disease after organ transplantation-United States, 2001. JAMA. 287:2002;1795-1796.
40. McQuiston J.H., Childs J.E., Chamberland M.E., Tabor E. Transmission of tick-borne agents of disease by blood transfusion: a review of known and potential risks in the United States. Transfusion. 40:2000;274-284.
41. Brown P., Preece M.A., Will R.G. Friendly fire in medicine: hormones, homografts, and Creutzfeldt-Jacob disease. Lancet. 340:1992;24-27.
42. Dodd R.Y., Sullivan M.T. Creutzfeldt-Jacob disease and transfusion safety: tilting at icebergs? Transfusion. 38:1998;221-223.
43. FDA. Revised preventative measures to reduce the possible risk of transmission of CJD and vCJD by blood and blood products. http://www.fda.gov/cber/gdlins/cjdvcjd.htm (acccessed Jan 8, 2002).
44. Blood transfusion accidents. BMJ. 2:1953;390-391.
45. Linden J.V., Wagner K., Voytovich A.E., Sheehan J. Transfusion errors in New York State: an analysis of 10 years' experience. Transfusion. 40:2001;1207-1213.
46. Williamson L.M., Lowe S., Love E., et al. Serious hazards of transfusion. Initiative: analysis of first two annual reports. BMJ. 319:1999;16-19.
47. Sazama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion. 30:1990;583-590.
48. Goldman M., Remy-Prince S., Trepanier A., Decary F. Autologous donation error rates in Canada. Transfusion. 37:1997;523-527.
49. American Association of Blood Bank. Non-infectious serious hazards of transfusion. Bethesda, MD: American Association of Blood Bank (Association bulletin 01-4), June 14, 2001.
50. Aubuchon J.P., Lipton K.S. Is it time for blood banking to take off? Transfusion. 41:2001;964-967.
51. Battles J.B., Kaplan H.S., Van Der Schaff T.W., Shea C.E. The attributes of medical event-reporting systems. Experience with a prototype medical event-reporting system for transfusion medicine. Arch Pathol Lab Med. 122:1988;231-238.
52. Callum J.L., Kaplan H.S., Merkley L.L., et al. Reporting of near-miss events for transfusion medicine: improving transfusion safety. Transfusion. 41:2001;1204-1211.
53. Wenz B., Burns E.R. Improvement in blood safety using a new blood unit and patient identification system as part of safe transfusion practice. Transfusion. 31:1991;401-403.
54. Jenson N.J., Crosson J.T. An automated system for bedside verification of the match between patient identification and blood group identification. Transfusion. 36:1996;216-221.
55. Goodnough L.T., Brecher M.E., Kanter M.H., Aubuchon J.P. Transfusion Medicine. Part I. N Engl J Med. 340:1999;438-447.
56. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 339:1998;584-590.
57. Foley R.N., Parfrey P.S., Harnett J.D., Kent G.M., Murray O.C., Barre P.C. The impact of anemia on cardiomyopathy, morbidity, and mortality in end state renal disease. Am J Kidney Dis. 28:1996;53-61.
58. Canella G., LaCamma G., Sandrini M., et al. Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic dialysed uraemic patients. Nephrol Dial Transplant. 6:1991;31-37.
59. Collins A., Ma J.Z., Ebben J., et al. Impact of hematocrit on morbidity and mortality. Semin Nephrol. 20:2000;345-349.
60. Ma J., Ebben J., Xia H., et al. Hct level and associated mortality in hemodialysis patients. J Am Soc Neph. 10:1999;610-619.
61. Collins A., Xia H., Ebben J., et al. Change in Hct and risk of mortality. J Am Soc Nephrol. 9:1998;204A.
62. Collins A.J., Li S., St Peter W., et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol. 12:2001;2465-2473.
63. Clinical practice guidelines for the treatment of anemia of chronic kidney disease. Am J Kidney Dis. 30:1997;S192-237.
64. Carson J.L., Duff A., Poses R.M., et al. Effect of anemia and cardiovascular disease on surgical mortality and morbidity. Lancet. 348:1996;1055-1060.
65. Hebert P.C., Wells G., Sweedale M., et al. Does transfusion practice affect mortality in critically ill patients? Crit Care Med. 155:1997;1618-1623.
66. Silverberg O.S., Wexler D., Sheps D., et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 37:2001;1776-1779.
67. Wu W.C., Rathmore S.S., Wang Y., Radford M.J., Krumholz H.M. Effectiveness of blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med. 345:2001;1230-1236.
68. Goodnough L.T., Bach R.G. Anemia, transfusion, and mortality. N Engl J Med. 345:2001;1272-1273.
69. Lenfant C. Transfusion should be monitored for undertransfusion as well as overtransfusion. Transfusion. 32:1992;873-874.
70. Sazama K. Is undertransfusion occurring? Transfusion. 41:2001;577-578.
71. National Heart, Lung, and Blood Institute. http://grants.nih.gov/grants/guide/rfa-files/rfa-HL-02-001.html (accessed Jan 2, 2002).
72. Goodnough L.T., Brecher M.E., AuBuchon J.P. Transfusion Medicine. Part II. Blood Conservation. N Engl J Med. 340:1999;525-533.
73. Hedner U., Erhardtsen E. Potential role for recombinant factor VIIa in transfusion medicine. Transfusion. 42:2002;114-124.
74. Winslow R.M. Blood substitutes - a moving target. Nat Med. 1:1995;1212-1215.
75. Stowell C.P., Levin J., Spiess B.D., Winslow R.M. Progress in the development of RBC substitutes. Transfusion. 41:2001;287-299.
76. Ma Z., Monk T.G., Goodnough L.T., et al. Effect of hemoglobin- and perflubron-based oxygen carriers on common clinical laboratory tests. Clin Chem. 43:1997;1732-1737.
77. Scott M.G., Kucik D.F., Goodnough L.T., Monk T.G. Blood substitutes: evolution and future applications. Clin Chem. 43:1997;1724-1731.
78. Rioux F., Drapeau G., Marceau F. Recombinant human hemoglobin selectively inhibits vasorelaxation elicited by nitric oxide donors in rabbit isolated aortic rings. J Cardiovasc Pharmacol. 25:1995;587-594.
79. Winslow R.M. Blood substitutes. Curr Opin Hematol. 9:2002;146-151.
80. Kasper S.M., Grune F., Walter M., Amr N., Erasmi H., Buzello W. The effects of increased doses of bovine hemoglobin on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery. Anesth Analg. 87:1998;284-291.
81. Sloan E.P., Koenigsberg M., Gens D., et al. Diaspirin cross-linked hemoglobin (DCL-Hgb) in the treatment of severe traumatic hemorrhagic shock. JAMA. 282:1999;1857-1864.
82. Keipert P.E. Use of Oxygent, a perfluorochemical-based oxygen carrier, as an alternative to intraoperative blood transfusion. Artif Cells Blood Substit Immobil Biotechnol. 23:1995;381-394.
83. Spahn D.R., van Brempt R., Theilmeier G., et al. Perflubron emulsion delays blood transfusions in orthopedic surgery. Anesthesiology. 91:1999;1195-1208.
84. Jones J.A. Red blood cell substitutes: current status. Br J Anaesth. 74:1995;697.
85. Maguire P.J., Stevens C., Humes H.D., Shander A., Halpern N.A., Pastores S.M. Bioartificial organ support for hepatic, renal, and hematologic failure. Crit Care Clin. 16:2000;681-684.
86. Spahn D.R., Leone B.J., Reves J.G., Pasch T. Cardiovascular and coronary physiology of acute isovolemic hemodilution: a review of nonoxygen-carrying and oxygen-carrying solutions. Anesth Analg. 78:1994;1000-1021.
87. Cothren C., Moore E.E., Offner P.J., Haenel J.B., Johnson J.L. Blood substitute and erythropoietin therapy in a severely injured Jehovah's Witness. N Engl J Med. 346:2002;1097-1098.
88. Brecher M.E., Goodnough L.T., Monk T. The value of oxygen-carrying solutions in the operative setting, as determined by mathematical modeling. Transfusion. 39:1999;396-402.
89. Mullon J., Giacoppe G., Clagett C., McCurie D., Dillard T. Transfusions of polymerized bovine hemoglobin in a patient with severe autoimmune hemolytic anemia. N Engl J Med. 342:2000;1638-1643.
90. Bandarenko N., Brecher M.E. United States thrombotic thrombocytopenic purpura apheresis study group: multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. J Clin Apheresis. 13:1998;133-141.
91. Bell W.R., Braine H.G., Ness P.M., Kickler T.S. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: clinical experience in 108 patients. N Engl J Med. 325:1991;398-403.
92. Clark W.F., Rock G.A., Buskard N., et al. Therapeutic plasma exchange: an update from the Canadian Apheresis Group. Ann Intern Med. 131:1999;453-462.
93. Furlan M., Robles R., Galbusera M., et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 339:1998;1578-1584.
94. Tsai H.M., Lian E.C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 339:1998;1585-1589.
95. Levy G.G., Nichols W.C., Lian E.C., et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 413:2001;488-494.
96. Fujikawa K., Suzuki H., McMullen B., Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood. 98:2001;1662-1666.
97. Gerritsen H.E., Robles R., Lammle B., Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood. 98:2001;1654-1661.
98. Zheng X., Chung D., Takayama T.K., Majerus E.M., Sadler J.E., Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 276:2001;41059-41063.
99. Goodnough L.T. What is a transfusion medicine specialist? Transfusion. 39:1999;1031-1033.
100. Noel L. Safe blood starts with me, blood saves lives. Transcripts of World Health Day 2000, April 7, 2000. http://www.who.int/multimedia/whd2000/#noel (accessed Jan 5, 2002).
101. C Health. Millions need access to safe blood, says UN. http://www.canoe.ca/Health0004/07blood.html (accessed Jan 5, 2002).